Ampullary cancer is a rare cancer that forms at the ampulla of Vater, the small opening where bile from the liver and digestive enzymes from the pancreas drain into the first part of the small intestine. It affects roughly 0.5 to 0.9 people per 100,000 each year. Because of its location at a critical digestive crossroads, ampullary cancer tends to cause noticeable symptoms earlier than other cancers in the same area, which often means it’s caught at a stage where surgery can still offer a chance at cure.
Where the Cancer Forms
The ampulla of Vater sits within the wall of the duodenum, about four inches into the first section of the small intestine. It’s where two important ducts converge: the common bile duct, which carries bile from the liver and gallbladder, and the pancreatic duct, which delivers digestive enzymes. These fluids merge at the ampulla and flow into the intestine to help break down food.
Because the ampulla is so small and sits at the junction of several different tissue types, a cancer here can involve intestinal tissue, bile duct tissue, or pancreatic duct tissue. That distinction matters more than it might seem, because the tissue type shapes both how the cancer behaves and how well treatment works.
Why Symptoms Often Appear Early
A tumor at the ampulla of Vater can block the flow of bile even when it’s still quite small. That blockage leads to a buildup of bile in the bloodstream, which produces jaundice, a yellowing of the skin and the whites of the eyes. Jaundice is often the first and most obvious sign.
Other common symptoms include:
- Clay-colored or pale stools (because bile isn’t reaching the intestine to give stool its normal brown color)
- Dark urine
- Unexplained weight loss
- Abdominal pain
- Nausea and vomiting
- Diarrhea
- Blood in the stool
- Fever
This early symptom profile is a meaningful advantage. Pancreatic cancer, which develops just inches away, often causes no symptoms until it has already spread. Ampullary tumors, by contrast, frequently announce themselves by blocking bile flow while the tumor is still localized and surgically removable.
Two Subtypes With Different Outlooks
Under a microscope, ampullary cancers generally fall into one of two categories based on which tissue type they most resemble. This distinction is one of the strongest predictors of how a patient will do after treatment.
The intestinal subtype looks similar to colon cancer. It tends to be better differentiated, meaning the cells still somewhat resemble normal tissue, and it generally carries a more favorable prognosis. The pancreatobiliary subtype resembles cancers of the bile duct or pancreas and behaves more aggressively. In studies of patients who underwent surgery, those with the pancreatobiliary subtype had roughly three to four times the risk of death compared to those with the intestinal subtype, even after accounting for tumor size, lymph node involvement, and other factors.
Pathologists determine the subtype after surgery by examining the tumor tissue. It’s not something patients can feel or detect on their own, but it heavily influences what doctors recommend for follow-up treatment.
How It’s Diagnosed
Because the ampulla sits deep inside the digestive tract, diagnosis typically involves endoscopic procedures rather than simple imaging. The most effective initial tool is ERCP (endoscopic retrograde cholangiopancreatography), a procedure where a flexible scope is passed through the mouth, down to the duodenum, and into the bile and pancreatic ducts. During ERCP, doctors can visualize the ampulla directly, take tissue samples, and even place a stent to relieve bile duct blockage.
ERCP combined with intraductal ultrasound achieves the highest diagnostic accuracy for ampullary tumors, around 88%. Standard CT scans are less reliable for detecting the primary tumor, with sensitivity around 47%, though they remain important for checking whether cancer has spread to lymph nodes or distant organs. Endoscopic ultrasound, which uses a probe at the tip of an endoscope, can visualize how deeply a tumor has invaded surrounding tissue and has shown sensitivity as high as 96% for detecting cancerous narrowing of the bile duct.
In practice, most patients end up getting a combination of these tests: endoscopy with biopsy to confirm the cancer, followed by CT or endoscopic ultrasound to determine how far it has spread.
Risk Factors and Genetic Conditions
Most ampullary cancers occur without a clear genetic cause. However, certain inherited conditions raise the risk substantially. Familial adenomatous polyposis (FAP), a condition caused by a mutation in the APC gene that leads to hundreds of polyps in the colon, also increases the risk of polyps at the ampulla of Vater. In people with FAP, the estimated chance of those ampullary polyps progressing to cancer is between 4% and 12%. Lynch syndrome, another inherited condition that raises colorectal cancer risk, is also associated with higher rates of ampullary tumors.
People with these genetic syndromes are typically monitored with regular endoscopic screening of the duodenum and ampulla, often starting in their 20s or 30s, so that precancerous polyps can be found and removed before they become malignant.
Surgery: The Primary Treatment
The Whipple procedure (pancreaticoduodenectomy), first described in 1935, remains the only potentially curative treatment for ampullary cancer. It’s a major operation that removes the head of the pancreas, the duodenum, the gallbladder, part of the bile duct, and sometimes a portion of the stomach. The remaining organs are then reconnected to allow digestion to continue.
This sounds drastic, and it is. But ampullary cancer patients tend to fare significantly better after a Whipple than pancreatic cancer patients undergoing the same surgery. Ampullary tumors are more often well-differentiated, less likely to invade surrounding nerves and blood vessels, and more frequently caught before lymph node spread. In comparative studies, ampullary tumors averaged about 2.2 cm at surgery compared to 3.5 cm for pancreatic cancers. Nerve invasion was present in only about 10% of ampullary cases versus 85% of pancreatic cases, and lymph node involvement was found in roughly 24% of ampullary cancers versus 69% of pancreatic cancers.
Variations of the Whipple exist, including pylorus-preserving versions that leave more of the stomach intact, as well as laparoscopic and robotic approaches that use smaller incisions. The choice depends on tumor size, location, and the surgical team’s expertise.
Chemotherapy After Surgery
After a Whipple procedure, many patients receive chemotherapy to reduce the chance of recurrence. The two most commonly used drugs are gemcitabine and capecitabine (an oral form of 5-fluorouracil). However, there is no universally agreed-upon standard regimen for ampullary cancer specifically, largely because the cancer is so rare that large clinical trials have been difficult to run. Treatment decisions are often borrowed from protocols designed for pancreatic or bile duct cancers.
Clinical trials are now underway to determine whether more aggressive multi-drug regimens improve outcomes. The ongoing AMPIRINOX trial, for instance, is comparing a modified four-drug combination against single-agent chemotherapy, with disease-free survival as the primary goal. Results from trials like this are expected to bring more clarity to post-surgical treatment in the coming years.
Survival Rates and Prognosis
Ampullary cancer’s prognosis varies enormously depending on the stage at diagnosis and the tumor subtype. For locally confined disease, the five-year survival rate ranges from 41% to 45% overall, though some studies report rates as high as 75% in the most favorable cases. For cancers that have spread to distant organs, the five-year survival drops to roughly 4% to 7%.
Several factors influence where a patient falls within that wide range. The histologic subtype is among the strongest: intestinal-type tumors carry a meaningfully better outlook than pancreatobiliary-type tumors. Lymph node involvement, invasion into blood vessels, and tumor size all independently worsen the prognosis. Clear surgical margins, meaning the surgeon was able to remove the tumor with a rim of healthy tissue around it, are also critical.
Compared to pancreatic cancer, which has a five-year survival rate of roughly 10% to 12% overall, ampullary cancer offers a considerably better outlook. This is largely because it tends to be caught earlier, responds more often to complete surgical removal, and less frequently displays the aggressive biological features that make pancreatic cancer so lethal.